The Most Comprehensive Pancreatic Cancer Preclinical Platform
Crown Bioscience offers an end-to-end suite of pancreatic cancer models — from rapid in vitro screening to fully immune-competent in vivo studies — all backed by deep genomic annotation and expert scientific support.
Daraxonrasib benchmark data across 100+ models (X PDAC) so you can contextualize your compound and build a differentiated story without generating reference data yourself.
PDX, matched organoids, KPC homografts, GEMMs, and cell line panels all annotated for KRAS mutation status and key co-alterations including TP53, SMAD4, and CDKN2A.
Matched PDXO and PDX pairs from the same patient let you screen in vitro and confirm in vivo in genetically concordant models, with organoid studies completing in weeks.
KPC homografts retain KRAS G12D, TP53 loss, desmoplastic morphology, and ICI resistance, making them the gold standard for IO combination and stromal-targeting studies.
WES, RNA-seq, proteomics, spatial biology, and custom PK/PD assays across the full PDAC portfolio, ready to support biomarker discovery and patient stratification.
Models evaluated with gemcitabine, nab-paclitaxel, FOLFIRINOX, and daraxonrasib so you can benchmark your candidate against current and emerging standards of care from day one.
Benchmark Your Program Against the Emerging KRAS Landscape
Daraxonrasib has become an important reference point in pancreatic cancer drug development. With benchmark data already generated across 100+ PDAC models, Crown Bioscience helps clients compare compound performance, identify differentiated response patterns, and strengthen preclinical positioning.
Utilize our PDAC model portfolio with daraxonrasib data to move faster in evaluating activity, prioritizing combinations, and building a compelling data package for internal decision-making and external stakeholders.
Drawing on Crown Bioscience’s deep pancreatic cancer expertise, including a portfolio of 100+ translational models and daraxonrasib benchmarking data, our speakers discuss how to bridge the gap between early preclinical discovery and more confident therapeutic decision-making.
Rekha Pal, PhD and Marten Hornsveld, PhD highlight how integrating pancreatic cancer organoids and in vivo models enables:
- Rapid Translational Screening: Utilizing patient-derived pancreatic cancer organoids to evaluate therapeutic sensitivity, support responder analysis, and prioritize candidates in a biologically relevant in vitro setting.
- Predictive In Vivo Validation: Leveraging pancreatic cancer in vivo models to assess efficacy, response durability, resistance mechanisms, and biomarker-linked outcomes in complex physiological contexts.
- Actionable Benchmarking Data: Showcasing daraxonrasib benchmarking data and Crown Bioscience’s broad pancreatic cancer portfolio to help researchers compare modalities, refine model selection, and advance KRAS-targeted, ADC, and combination strategies with greater confidence.
Matched patient-derived organoids enable rapid in vitro screening and can be paired with corresponding PDX models for stronger translational continuity.
Our PDAC PDX collection supports in vivo efficacy studies, resistance modeling, and biomarker research across clinically relevant molecular subtypes.
.webp)
GEMMs support mechanistic studies, pathway biology, and resistance research in genetically defined pancreatic cancer settings.
.webp)
